| 2023-11-07 | +37.0% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-08 | +36.4% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-08 | +36.4% | legal | Stock Titan | Axogen, Inc. Reports Second Quarter 2024 Financial Results - Stock Titan |
| 2025-05-08 | -31.2% | executive | Seeking Alpha | Axogen names Lindsey Hartley as finance chief |
| 2025-05-08 | -31.2% | earnings | Seeking Alpha | AxoGen Non-GAAP EPS of -$0.02 misses by $0.04, revenue of $48.56M beats by $0.21M |
| 2025-05-08 | -31.2% | legal | SEC EDGAR | AXGN 8-K: 2.02, 5.02 (SEC Filing) |
| 2024-01-04 | +29.1% | legal | SEC EDGAR | AXGN 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2025-10-29 | +26.5% | earnings | Seeking Alpha | Axogen raises 2025 revenue growth target to at least 19% as BLA for Avance Nerve Graft nears key milestone |
| 2025-10-29 | +26.5% | earnings | Seeking Alpha | Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript |
| 2025-10-29 | +26.5% | earnings | Seeking Alpha | AxoGen Non-GAAP EPS of $0.12 beats by $0.05, revenue of $60.1M beats by $3.2M |
| 2025-10-29 | +26.5% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-10-29 | +26.5% | earnings | Yahoo Finance | AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance |
| 2024-01-05 | +25.7% | legal | SEC EDGAR | AXGN 8-K: 5.02 and (SEC Filing) |
| 2025-10-28 | +24.9% | earnings | Seeking Alpha | AxoGen Q3 2025 Earnings Preview |
| 2025-05-07 | -24.4% | earnings | Seeking Alpha | AxoGen Q1 2025 Earnings Preview |
| 2022-05-04 | +24.0% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2023-08-07 | -21.2% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-10 | +20.9% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-11-08 | +20.5% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-07 | -18.6% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-03 | +18.3% | earnings | Stock Titan | Axogen (NASDAQ: AXGN) secures FDA BLA approval for Avance biologic, U.S. launch expected in Q2 2026 - Stock Titan |
| 2025-12-04 | +17.4% | legal | Seeking Alpha | Axogen gets FDA OK for Avances biologics license application |
| 2025-12-04 | +17.4% | legal | SEC EDGAR | AXGN 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-04 | +17.4% | news | Stocktwits | Why Is AXGN Stock Rising Today? - Stocktwits |
| 2025-12-04 | +17.4% | analyst | Investing.com | AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com |
| 2025-12-04 | +17.4% | news | Benzinga | Why Is Axogen Stock Soaring Thursday? - Axogen (NASDAQ:AXGN) - Benzinga |
| 2025-12-04 | +17.4% | legal | parameter.io | Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io |
| 2025-07-22 | +15.1% | legal | Quiver Quantitative | Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News - Quiver Quantitative |
| 2021-11-03 | -14.3% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-05-05 | +14.1% | legal | SEC EDGAR | AXGN 8-K: 2.02 and 7.01 (SEC Filing) |
| 2024-03-05 | -13.9% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-05-02 | -13.9% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-24 | -13.3% | earnings | Seeking Alpha | Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position |
| 2026-02-24 | -13.3% | earnings | Seeking Alpha | Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript |
| 2026-02-24 | -13.3% | earnings | Seeking Alpha | Axogen, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-24 | -13.3% | earnings | Seeking Alpha | AxoGen Non-GAAP EPS of $0.07 misses by $0.03, revenue of $59.9M in-line |
| 2026-02-24 | -13.3% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-24 | -13.3% | news | The Motley Fool | HighMark Wealth Management Buys 158,855 Shares of Axogen Stock - The Motley Fool |
| 2026-02-24 | -13.3% | legal | Stock Titan | FDA-approved nerve graft helps Axogen grow sales 20% in 2025 - Stock Titan |
| 2026-02-24 | -13.3% | earnings | Yahoo Finance | AxoGen (AXGN) Q4 Earnings Miss Estimates - Yahoo Finance |
| 2025-05-09 | -12.7% | earnings | Seeking Alpha | Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript |
| 2022-02-22 | +10.8% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-03-14 | +10.5% | legal | SEC EDGAR | AXGN 8-K: 2.02 and 7.01 (SEC Filing) |
| 2025-08-05 | +9.3% | earnings | Seeking Alpha | Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears |
| 2025-08-05 | +9.3% | earnings | Seeking Alpha | Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript |
| 2025-08-05 | +9.3% | earnings | Seeking Alpha | Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-05 | +9.3% | earnings | Seeking Alpha | AxoGen Non-GAAP EPS of $0.12 beats by $0.06, revenue of $56.66M beats by $4.05M |
| 2025-08-05 | +9.3% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-25 | +8.5% | legal | SEC EDGAR | AXGN 8-K: 2.02 and 7.01 (SEC Filing) |
| 2026-01-23 | +8.0% | legal | SEC EDGAR | AXGN 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-01-23 | +8.0% | news | MSN | Axogen stock dips after pricing $124M offering - MSN |
| 2026-01-07 | +7.8% | news | Yahoo Finance | Should You Think About Buying Axogen, Inc. (NASDAQ:AXGN) Now? - Yahoo Finance |
| 2026-01-12 | -7.7% | earnings | Seeking Alpha | Axogen sees Q4 net sales of up to $59.9M and FY2025 at $225.2M |
| 2026-01-12 | -7.7% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-12 | -7.7% | news | Quiver Quantitative | Axogen, Inc. Reports Strong Preliminary Fourth Quarter and Full-Year 2025 Financial Results - Quiver Quantitative |
| 2026-02-23 | -7.6% | earnings | Seeking Alpha | AxoGen Q4 2025 Earnings Preview |
| 2026-04-15 | +7.4% | news | Simply Wall St. | Assessing Axogen (AXGN) Valuation After Strong Recent Share Price Momentum |
| 2025-08-04 | +7.3% | earnings | Seeking Alpha | AxoGen Q2 2025 Earnings Preview |
| 2025-10-21 | +6.9% | news | simplywall.st | With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st |
| 2022-08-25 | -6.6% | legal | SEC EDGAR | AXGN 8-K: 1.01 and (SEC Filing) |
| 2023-12-06 | +6.6% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-12-05 | -6.2% | legal | SEC EDGAR | AXGN 8-K: 5.02 and (SEC Filing) |
| 2025-12-05 | -6.2% | analyst | Investing.com | AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com |
| 2026-04-20 | -5.9% | news | GlobeNewswire | CVRx Announces Nomination of Michael Dale for Election to the Board of Directors |
| 2022-01-31 | +5.8% | legal | SEC EDGAR | AXGN 8-K: 1.01 (SEC Filing) |
| 2024-03-08 | -5.7% | legal | SEC EDGAR | AXGN 8-K: 5.02 and (SEC Filing) |
| 2026-04-05 | -5.7% | earnings | MarketBeat | SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN - MarketBeat |
| 2026-01-24 | +5.2% | news | Yahoo Finance | A Look At Axogen (AXGN) Valuation After Its Upsized US$124 Million Equity Offering - Yahoo Finance |
| 2026-03-02 | -5.2% | news | Nasdaq | Axogen, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq |
| 2026-03-02 | -5.2% | executive | Stock Titan | Axogen (AXGN) innovation chief reports stock awards and tax-share withholding - Stock Titan |
| 2026-03-02 | -5.2% | news | Stock Titan | Axogen (NASDAQ: AXGN) EVP reports RSU vesting and tax share withholding - Stock Titan |
| 2026-03-02 | -5.2% | news | Stock Titan | Axogen (AXGN) CMO granted 23,000 RSUs and adjusts share holdings - Stock Titan |
| 2026-03-17 | -4.6% | news | TradingView | Do Options Traders Know Something About Axogen Stock We Don't? - TradingView |
| 2026-03-24 | +4.6% | earnings | Motley Fool | Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know |
| 2026-03-24 | +4.6% | earnings | The Motley Fool | Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know - The Motley Fool |
| 2022-11-10 | -4.5% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for AxoGen (AXGN) - Zacks Investment Research |
| 2022-05-26 | +4.3% | legal | SEC EDGAR | AXGN 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-01-16 | +4.2% | legal | DirectorsTalk Interviews | AxoGen, Inc. (AXGN) Stock Analysis: A Promising 18.51% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews |
| 2025-08-12 | +3.9% | news | Seeking Alpha | Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined |
| 2025-08-12 | +3.9% | news | Seeking Alpha | Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha |
| 2022-07-18 | +3.9% | legal | SEC EDGAR | AXGN 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-04-22 | +3.6% | earnings | Motley Fool | Axogen (AXGN) Q2 2025 Earnings Transcript |
| 2026-04-22 | +3.6% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | AXGN (Axogen Inc.) posts 20.2 percent year over year revenue growth in Q4 2025, shares edge higher even as EPS misses estimates. - Popular Trader Picks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-02-27 | -3.5% | analyst | DirectorsTalk Interviews | AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal A 22.88% Upside Potential - DirectorsTalk Interviews |
| 2022-07-11 | +3.4% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-02 | -3.4% | news | Insider Monkey | What Makes Axogen (AXGN) an Investment Bet? |
| 2026-04-02 | -3.4% | news | Yahoo Finance | What Makes Axogen (AXGN) an Investment Bet? - Yahoo Finance |
| 2026-04-02 | -3.4% | earnings | MarketBeat | F&V Capital Management LLC Purchases Shares of 176,995 AxoGen, Inc. $AXGN - MarketBeat |
| 2023-06-30 | -3.3% | legal | SEC EDGAR | AXGN 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-18 | -3.2% | executive | Stock Titan | Axogen (AXGN) CFO nets shares from 9,000 RSU vesting as company withholds stock for taxes - Stock Titan |
| 2025-12-01 | -3.1% | legal | Seeking Alpha | Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen |
| 2025-12-01 | -3.1% | legal | Seeking Alpha | Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN) - Seeking Alpha |
| 2026-03-13 | +3.0% | legal | DirectorsTalk Interviews | AxoGen, Inc. (AXGN) Stock Analysis: Navigating the 27.69% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews |
| 2023-01-09 | -2.8% | legal | SEC EDGAR | AXGN 8-K: 2.02 and 7.01 (SEC Filing) |
| 2024-07-23 | +2.7% | legal | Stock Titan | Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 - Stock Titan |
| 2021-08-04 | -2.6% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-26 | -2.5% | news | Stock Titan | Vanguard realigns reporting; Axogen (NASDAQ: AXGN) shows 0 shares owned - Stock Titan |
| 2022-04-01 | +2.4% | legal | SEC EDGAR | AXGN 8-K: 5.02 (SEC Filing) |
| 2022-08-16 | -2.4% | analyst | TradingView | AXGN Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-11-03 | +2.3% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2024-09-17 | +2.1% | news | Seeking Alpha | AxoGen: An Intriguing Growth Story (NASDAQ:AXGN) - Seeking Alpha |
| 2026-02-25 | -2.1% | earnings | Seeking Alpha | Axogen Q4: EPS Miss Amid Biologics Transition |
| 2026-02-25 | -2.1% | earnings | Seeking Alpha | Axogen Q4: EPS Miss Amid Biologics Transition (NASDAQ:AXGN) - Seeking Alpha |
| 2026-03-21 | +2.1% | earnings | The Globe and Mail | This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth - The Globe and Mail |
| 2025-07-29 | +2.0% | M&A | Seeking Alpha | Axogen gains on report of takeover interest |
| 2025-08-31 | -1.9% | news | Yahoo Finance | With 88% ownership of the shares, Axogen, Inc. (NASDAQ:AXGN) is heavily dominated by institutional owners - Yahoo Finance |
| 2026-04-14 | +1.8% | news | GlobeNewswire | Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026 |
| 2026-04-14 | +1.8% | earnings | Stock Titan | Axogen investors get Q1 results April 28, webcast starts at 8 a.m. ET - Stock Titan |
| 2023-05-09 | -1.8% | legal | SEC EDGAR | AXGN 8-K: 2.02 and (SEC Filing) |
| 2026-01-03 | +1.8% | earnings | simplywall.st | Axogen, Inc. (NASDAQ:AXGN) Could Be Less Than A Year Away From Profitability - simplywall.st |
| 2021-09-21 | +1.7% | news | GuruFocus | Axogen Inc (AXGN) Stock Price & 30 Year Financial Data - GuruFocus |
| 2025-07-02 | -1.5% | news | Yahoo Finance | Axogen Showcases Nerve Repair Vision at Goldman Sachs - Yahoo Finance |
| 2025-11-04 | +1.4% | news | simplywall.st | Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump - simplywall.st |
| 2026-04-17 | -1.4% | news | Zacks | AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains? |
| 2026-04-17 | -1.4% | news | Yahoo Finance | AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance |
| 2026-04-17 | -1.4% | legal | DirectorsTalk Interviews | AxoGen, Inc. (AXGN) Stock Analysis: A Promising Upside In The Healthcare Sector - DirectorsTalk Interviews |
| 2025-08-14 | +1.4% | news | Investing.com | AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com |
| 2026-01-21 | -1.3% | news | Seeking Alpha | Axogen announces proposed $85M public stock offering; shares down |
| 2026-01-21 | -1.3% | news | Quiver Quantitative | Axogen, Inc. Plans $85 Million Public Offering of Common Stock - Quiver Quantitative |
| 2026-01-21 | -1.3% | news | Stock Titan | Axogen plans $85M stock sale to repay loan and fund operations - Stock Titan |
| 2026-01-21 | -1.3% | news | Investing.com | Axogen stock falls after $85 million share offering announcement - Investing.com |
| 2026-01-21 | -1.3% | news | GlobeNewswire | Axogen Announces Proposed Public Offering of Common Stock - GlobeNewswire |
| 2026-01-21 | -1.3% | news | MSN | Axogen announces proposed $85M public stock offering; shares down - MSN |
| 2026-01-21 | -1.3% | news | Investing.com | Axogen plans $85 million stock offering to repay debt - Investing.com |
| 2022-10-31 | +1.2% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-01-22 | -1.1% | news | Seeking Alpha | Axogen stock dips after pricing $124M offering |
| 2024-08-09 | +1.1% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-21 | -1.0% | earnings | Zacks | AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth |
| 2026-04-21 | -1.0% | earnings | MarketBeat | AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat |
| 2026-04-21 | -1.0% | expansion | marketscreener.com | Certain Restricted Stock Units of Axogen, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026. - marketscreener.com |
| 2026-03-06 | +0.9% | news | Seeking Alpha | Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript |
| 2022-01-10 | -0.8% | legal | SEC EDGAR | AXGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-01 | -0.8% | legal | SEC EDGAR | AXGN 8-K: 5.08 and 8.01 (SEC Filing) |
| 2024-06-07 | -0.8% | legal | SEC EDGAR | AXGN 8-K: 5.02, 5.07 (SEC Filing) |
| 2023-12-26 | -0.7% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-07-19 | +0.7% | legal | SEC EDGAR | AXGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-07-16 | -0.7% | legal | SEC EDGAR | AXGN 8-K: 1.01 and (SEC Filing) |
| 2024-05-11 | +0.7% | earnings | MarketBeat | AxoGen (AXGN) Stock Forecast and Price Target 2026 - MarketBeat |
| 2022-08-03 | +0.6% | legal | SEC EDGAR | AXGN 8-K: 2.02 and 7.01 (SEC Filing) |
| 2025-10-30 | +0.6% | earnings | Seeking Alpha | Axogen, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-12-12 | +0.6% | news | simplywall.st | Trade Alert: President Of Axogen Michael Dale Has Sold Stock - simplywall.st |
| 2026-01-15 | +0.5% | news | Seeking Alpha | Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-02-19 | -0.3% | analyst | Benzinga | This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga |
| 2025-08-25 | -0.3% | legal | Seeking Alpha | Axogen falls 16% after FDA delays Avance Nerve Graft decision to December |
| 2025-08-25 | -0.3% | legal | Quiver Quantitative | Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review - Quiver Quantitative |
| 2025-11-27 | -0.2% | news | Yahoo Finance | Axogen (NASDAQ:AXGN) shareholder returns have been strong, earning 161% in 3 years - Yahoo Finance |
| 2023-09-22 | -0.2% | legal | SEC EDGAR | AXGN 8-K: 5.02 (SEC Filing) |
| 2026-04-26 | — | news | Motley Fool | Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million |
| 2026-04-24 | — | news | Simply Wall St. | Is It Too Late To Consider Axogen (AXGN) After Its 1‑Year Share Price Surge? |